Dae Gon Ha
Stock Analyst at Stifel
(2.31)
# 2,533
Out of 4,843 analysts
49
Total ratings
35.9%
Success rate
2.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dae Gon Ha
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ABEO Abeona Therapeutics | Maintains: Buy | $21 → $20 | $6.24 | +220.77% | 2 | May 16, 2025 | |
| EDIT Editas Medicine | Downgrades: Hold | $11 → $3 | $1.72 | +74.42% | 4 | Dec 13, 2024 | |
| SLNO Soleno Therapeutics | Maintains: Buy | $59 → $74 | $73.35 | +0.89% | 2 | Oct 1, 2024 | |
| FULC Fulcrum Therapeutics | Downgrades: Hold | $22 → $3 | $6.88 | -56.40% | 4 | Sep 12, 2024 | |
| INZY Inozyme Pharma | Initiates: Buy | $16 | $3.97 | +303.02% | 1 | Sep 12, 2024 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $80 → $64 | $6.87 | +831.59% | 2 | Sep 11, 2024 | |
| KRYS Krystal Biotech | Maintains: Buy | $204 → $220 | $126.17 | +74.37% | 4 | Sep 11, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Buy | $48 → $66 | $44.42 | +48.58% | 3 | Jun 20, 2024 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $124 → $127 | $34.03 | +273.20% | 2 | May 31, 2024 | |
| VERV Verve Therapeutics | Maintains: Buy | $56 → $40 | $4.45 | +798.88% | 3 | Apr 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $48 | $2.51 | +1,812.35% | 4 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $1.18 | +1,425.42% | 1 | Apr 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7 | $0.39 | +1,694.87% | 1 | Mar 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $23 → $25 | $61.33 | -59.24% | 4 | Jun 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $12 → $16 | $6.07 | +163.59% | 3 | Nov 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $285 | $8.50 | +3,252.94% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $1.68 | +1,094.03% | 1 | May 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.42 | - | 2 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $16.93 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $10.75 | - | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.80 | +1,395.33% | 1 | Jun 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $600 → $490 | $8.37 | +5,754.24% | 2 | Oct 23, 2017 |
Abeona Therapeutics
May 16, 2025
Maintains: Buy
Price Target: $21 → $20
Current: $6.24
Upside: +220.77%
Editas Medicine
Dec 13, 2024
Downgrades: Hold
Price Target: $11 → $3
Current: $1.72
Upside: +74.42%
Soleno Therapeutics
Oct 1, 2024
Maintains: Buy
Price Target: $59 → $74
Current: $73.35
Upside: +0.89%
Fulcrum Therapeutics
Sep 12, 2024
Downgrades: Hold
Price Target: $22 → $3
Current: $6.88
Upside: -56.40%
Inozyme Pharma
Sep 12, 2024
Initiates: Buy
Price Target: $16
Current: $3.97
Upside: +303.02%
Intellia Therapeutics
Sep 11, 2024
Maintains: Buy
Price Target: $80 → $64
Current: $6.87
Upside: +831.59%
Krystal Biotech
Sep 11, 2024
Maintains: Buy
Price Target: $204 → $220
Current: $126.17
Upside: +74.37%
Mirum Pharmaceuticals
Jun 20, 2024
Maintains: Buy
Price Target: $48 → $66
Current: $44.42
Upside: +48.58%
Ultragenyx Pharmaceutical
May 31, 2024
Maintains: Buy
Price Target: $124 → $127
Current: $34.03
Upside: +273.20%
Verve Therapeutics
Apr 3, 2024
Maintains: Buy
Price Target: $56 → $40
Current: $4.45
Upside: +798.88%
Sep 13, 2023
Reiterates: Buy
Price Target: $48
Current: $2.51
Upside: +1,812.35%
Apr 18, 2023
Initiates: Buy
Price Target: $18
Current: $1.18
Upside: +1,425.42%
Mar 24, 2023
Maintains: Buy
Price Target: $12 → $7
Current: $0.39
Upside: +1,694.87%
Jun 17, 2022
Maintains: Buy
Price Target: $23 → $25
Current: $61.33
Upside: -59.24%
Nov 15, 2021
Upgrades: Buy
Price Target: $12 → $16
Current: $6.07
Upside: +163.59%
Sep 7, 2021
Initiates: Buy
Price Target: $285
Current: $8.50
Upside: +3,252.94%
May 3, 2021
Initiates: Buy
Price Target: $20
Current: $1.68
Upside: +1,094.03%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $7.42
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $16.93
Upside: -
Jun 17, 2020
Initiates: Neutral
Price Target: n/a
Current: $10.75
Upside: -
Jun 17, 2020
Initiates: Buy
Price Target: $12
Current: $0.80
Upside: +1,395.33%
Oct 23, 2017
Maintains: Outperform
Price Target: $600 → $490
Current: $8.37
Upside: +5,754.24%